[go: up one dir, main page]

ES2038190T3 - Ester morfolinoetilico de acido micofenolico y derivados del mismo, su preparacion y uso en composiciones farmaceuticas. - Google Patents

Ester morfolinoetilico de acido micofenolico y derivados del mismo, su preparacion y uso en composiciones farmaceuticas.

Info

Publication number
ES2038190T3
ES2038190T3 ES198787311021T ES87311021T ES2038190T3 ES 2038190 T3 ES2038190 T3 ES 2038190T3 ES 198787311021 T ES198787311021 T ES 198787311021T ES 87311021 T ES87311021 T ES 87311021T ES 2038190 T3 ES2038190 T3 ES 2038190T3
Authority
ES
Spain
Prior art keywords
derivatives
preparation
pharmaceutical compositions
mycophenolic acid
morpholinoethyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787311021T
Other languages
English (en)
Inventor
Peter H. Nelson
Anthony C. Allison
William A. Lee
Chee-Liang Leo Gu
Elsie M. Eugui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21733252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2038190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2038190T3 publication Critical patent/ES2038190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LOS COMPUESTOS FARMACEUTICOS DE FORMULA A, EN LA QUE Z ES HIDROGENO O -C(O)R, SIENDO R ALQUILO DE CADENA CORTA O ARILO, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, SON UTILES COMO AGENTES INMUNOSUPRESORES, ANTIINFLAMATORIOS, ANTITUMORALES, ANTIVIRICOS Y ANTI-PSORIASIS.
ES198787311021T 1987-01-30 1987-12-15 Ester morfolinoetilico de acido micofenolico y derivados del mismo, su preparacion y uso en composiciones farmaceuticas. Expired - Lifetime ES2038190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/008,717 US4753935A (en) 1987-01-30 1987-01-30 Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2038190T3 true ES2038190T3 (es) 1993-07-16

Family

ID=21733252

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787311021T Expired - Lifetime ES2038190T3 (es) 1987-01-30 1987-12-15 Ester morfolinoetilico de acido micofenolico y derivados del mismo, su preparacion y uso en composiciones farmaceuticas.

Country Status (26)

Country Link
US (7) US4753935A (es)
EP (1) EP0281713B1 (es)
JP (1) JPS63188672A (es)
KR (1) KR940003758B1 (es)
AT (1) ATE68180T1 (es)
AU (1) AU599728B2 (es)
CA (1) CA1333285C (es)
DE (2) DE19675020I2 (es)
DK (1) DK166675B1 (es)
ES (1) ES2038190T3 (es)
FI (1) FI85141C (es)
GE (1) GEP20094816B (es)
GR (1) GR3002866T3 (es)
HK (1) HK125893A (es)
HU (2) HU201927B (es)
IE (1) IE60750B1 (es)
IL (1) IL84833A (es)
LU (1) LU88795I2 (es)
LV (1) LV5748B4 (es)
MX (1) MX9203163A (es)
NL (1) NL960019I2 (es)
NO (2) NO171680C (es)
NZ (1) NZ222922A (es)
PH (1) PH23819A (es)
PT (1) PT86343B (es)
ZA (1) ZA879414B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
DE69033342T2 (de) * 1989-02-23 2000-05-11 University Of North Carolina At Chapel Hill, Chapel Hill Etoposidanaloge
US5219851A (en) * 1991-03-05 1993-06-15 Warner-Lambert Company Tetrahydroisoquinoline-type renin inhibiting peptides
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CA2165794A1 (en) * 1993-06-25 1995-01-05 Brian Daunter Therapeutic agent
SI9420052B (sl) * 1993-09-15 2004-02-29 Syntex (U.S.A.) Inc. Kristalni brezvodni mikofenolatni mofetil in njegova intravenozna formulacija
CZ291231B6 (cs) * 1993-10-01 2003-01-15 Syntex (U.S.A.) Inc. Farmaceutický prostředek obsahující mofetil mykofenolát nebo kyselinu mykofenolovou, a způsob jeho přípravy
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5525602A (en) * 1994-02-18 1996-06-11 Syntex (U.S.A.) Inc. Method of using 4-amino 6-substituted mycophenolic acid and derivatives
US5512568A (en) * 1994-02-18 1996-04-30 Syntex (U.S.A.) Inc. Method of using 4-amino derivatives of 5-substituted mycophenolic acid
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6225073B1 (en) * 1994-07-07 2001-05-01 Dade Behring Marburg Gmbh Immunoassay for mycophenolic acid
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
CA2348267A1 (en) * 1998-10-29 2000-05-11 Henry H. Gu Novel inhibitors of impdh enzyme
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
IN188985B (es) 1998-12-09 2002-11-30 Biocon Ltd
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US6107052A (en) * 1999-06-09 2000-08-22 Roche Diagnostics Corporation Enzymatic measurement of mycophenolic acid
AU5553801A (en) * 2000-04-24 2001-11-07 Bristol Myers Squibb Co Heterocycles that are inhibitors of impdh enzyme
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20040127435A1 (en) * 2002-08-02 2004-07-01 Regents Of The University Of California Uses for inhibitors of inosine monophosphate dehydrogenase
TWI221414B (en) * 2003-02-21 2004-10-01 Chunghwa Chemical Synthesis & Method of making mycophenolate mofetil using transesterification
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
AU2003231924A1 (en) * 2003-04-07 2004-11-01 Biocon Limited Microwave synthesis of mycophenolate
WO2004100945A1 (en) * 2003-05-14 2004-11-25 Dsm Ip Assets B.V. Use of phthalide derivatives for the treatment and prevention of diabetes mellitus
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
CA2537958C (en) * 2003-09-11 2013-06-11 Sandoz Ag Process for the production of mycophenolate mofetil
JP2007505854A (ja) * 2003-09-23 2007-03-15 ディーエスエム アイピー アセッツ ビー．ブイ． 糖尿病の治療および予防用組成物
AU2003272083A1 (en) * 2003-10-07 2005-04-21 Biocon Limited Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
JP2007532585A (ja) * 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
JP2007534697A (ja) * 2004-04-27 2007-11-29 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸モフェチルおよび他のミコフェノール酸エステルの調製方法
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
TW200611692A (en) * 2004-07-20 2006-04-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
AU2005274681A1 (en) * 2004-08-16 2006-02-23 Verva Pharmaceuticals Pty Ltd Metabolism-modulating agents and uses therefor
CA2533326C (en) * 2005-01-20 2012-01-03 Apotex Fermentation Inc. An improved process for the preparation of mycophenolate mofetil
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CN100402516C (zh) * 2005-10-18 2008-07-16 深圳市东阳光实业发展有限公司 一种霉酚酸莫啡酯的制备方法
AU2007214784A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (MPA)
WO2008003637A2 (en) * 2006-07-05 2008-01-10 Dsm Ip Assets B.V. Isolation and use of amine salts of mycophenolic acid
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20080188653A1 (en) * 2007-02-04 2008-08-07 Formosa Laboratories, Inc. Process for Preparation of Mycophenolate Mofetil
CN100484930C (zh) * 2007-03-16 2009-05-06 重庆大新药业股份有限公司 一种吗替麦考酚酯的制备方法
WO2009000834A1 (en) * 2007-06-27 2008-12-31 Dsm Ip Assets B.V. Method for the purification of mycophenolate mofetil
WO2009010503A1 (en) * 2007-07-18 2009-01-22 Dsm Ip Assets B.V. Mycophenolic acid recycling in a method for the preparation of mycophenolate mofetil
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009084008A1 (en) * 2007-12-28 2009-07-09 Cadila Healthcare Limited Process for preparing mycophenolate mofetil
KR100975520B1 (ko) * 2008-02-01 2010-08-12 종근당바이오 주식회사 마이코페놀레이트 모페틸의 개선된 제조방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010004435A2 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
TW201026716A (en) * 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside analogs
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
FI20096026A7 (fi) 2009-10-06 2011-04-07 Maricap Oy Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
FI124873B (fi) 2009-10-06 2015-02-27 Maricap Oy Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102952105A (zh) * 2011-08-26 2013-03-06 中国科学院上海药物研究所 一类霉酚酸衍生物、其制备方法和用途
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10369133B2 (en) 2013-07-23 2019-08-06 The University Of Tennessee Research Foundation Immunosuppressive compounds and therapeutics
KR101856889B1 (ko) * 2014-01-10 2018-05-10 후지필름 가부시키가이샤 5-하이드록시-1h-이미다졸-4-카복사마이드의 유효 투여량 또는 감수성의 예측 방법 및 예측 장치, 잔토신 1인산의 양의 측정 방법 그리고 골수 이형성 증후군의 처치제 및 처치 방법
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US12011429B2 (en) 2016-06-02 2024-06-18 Steven Baranowitz Prevention and treatment of viral infections
US10603299B2 (en) 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
CA3026241A1 (en) 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
US10835489B2 (en) * 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
CN110526885A (zh) * 2019-08-20 2019-12-03 上海英诺富成生物科技有限公司 麦考酚酸的前体药物及其制备方法
CN113549040B (zh) * 2020-04-23 2024-08-06 鲁南制药集团股份有限公司 一种吗替麦考酚酯杂质d的制备方法
CN112121173B (zh) * 2020-08-22 2022-05-06 浙江大学 脂肪酸修饰的免疫抑制剂mmf及fk506纳米制剂及其制备方法和应用
EP4301380A1 (en) 2021-03-03 2024-01-10 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS5542995B2 (es) * 1972-02-24 1980-11-04
JPS5529994B2 (es) * 1972-03-02 1980-08-07
JPS563353B2 (es) * 1972-03-02 1981-01-24
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US3905894A (en) * 1973-10-02 1975-09-16 Murskauskone Oy Apparatus for wet fine screening
JPS5724380A (en) * 1980-07-22 1982-02-08 Chugai Pharmaceut Co Ltd Preparation of mycophenolic acid derivative
JPS57183776A (en) * 1981-05-01 1982-11-12 Ajinomoto Co Inc Preparation of mycophenolic acid derivative
JPS57183777A (en) * 1981-05-01 1982-11-12 Ajinomoto Co Inc Preparation of mycophenolic acid derivative
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva

Also Published As

Publication number Publication date
GR3002866T3 (en) 1993-01-25
LU88795I2 (fr) 1996-11-05
NZ222922A (en) 1990-09-26
US4992467A (en) 1991-02-12
NO171680C (no) 1993-04-21
LV5748B4 (lv) 1997-02-20
NL960019I1 (nl) 1996-10-01
NO171680B (no) 1993-01-11
FI875502L (fi) 1988-07-31
IL84833A (en) 1992-03-29
DK658787D0 (da) 1987-12-15
IE60750B1 (en) 1994-08-10
NO875240D0 (no) 1987-12-15
FI85141B (fi) 1991-11-29
US4753935A (en) 1988-06-28
HU201927B (en) 1991-01-28
FI875502A0 (fi) 1987-12-15
HU210350A9 (en) 1995-03-28
US4868153A (en) 1989-09-19
EP0281713B1 (en) 1991-10-09
MX9203163A (es) 1992-07-31
IE873397L (en) 1988-07-30
LV5748A4 (lv) 1996-10-20
US4952579A (en) 1990-08-28
FI85141C (fi) 1992-03-10
NO1997007I1 (no) 1997-07-01
AU8254087A (en) 1988-08-04
JPH0571591B2 (es) 1993-10-07
US4808592A (en) 1989-02-28
IL84833A0 (en) 1988-06-30
DE19675020I2 (de) 2002-11-07
US4948793A (en) 1990-08-14
NL960019I2 (nl) 1997-06-02
DE3773660D1 (de) 1991-11-14
PT86343A (en) 1988-01-01
GEP20094816B (en) 2009-11-10
DK658787A (da) 1988-07-31
NO875240L (no) 1988-08-01
KR940003758B1 (ko) 1994-04-30
PT86343B (pt) 1991-02-08
DK166675B1 (da) 1993-06-28
KR880009016A (ko) 1988-09-13
EP0281713A1 (en) 1988-09-14
PH23819A (en) 1989-11-23
ZA879414B (en) 1989-08-30
US4786637A (en) 1988-11-22
CA1333285C (en) 1994-11-29
HUT47567A (en) 1989-03-28
ATE68180T1 (de) 1991-10-15
AU599728B2 (en) 1990-07-26
HK125893A (en) 1993-11-19
JPS63188672A (ja) 1988-08-04

Similar Documents

Publication Publication Date Title
ES2038190T3 (es) Ester morfolinoetilico de acido micofenolico y derivados del mismo, su preparacion y uso en composiciones farmaceuticas.
ES2118283T3 (es) Derivados de acidos benzofuranil- y -tiofenil-alcanocarboxilicos.
ES8601994A1 (es) Un procedimiento para la preparacion de pirazolo-y piridazo-pirazolinas,-piridazinas y-diazepinas.
AR248139A1 (es) Procedimiento para obtener compuestos del acido 7-acil-3-vinil-3-cefem-4-carboxilico y sus sales.
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2086371T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
FI951614A0 (fi) D-vitamiinisarjan 25-karboksyylihappojohdannaisia, menetelmät niiden valmistamiseksi, näissä menetelmissä käytettävät välituotteet, näitä johdansia sisältävät farmaseuttiset valmisteet ja näiden johdannaisten käyttö lääkeaineiden valmistukseen
MX9300786A (es) Compuestos hipolipidaemicos.
ES8107201A1 (es) Un procedimiento para la preparacion de derivados de morfo- lina
ES2130472T3 (es) Guanididas de acidos alquenilcarboxilicos sustituidas con fenilo, portadoras de grupos perfluoroalquilo, procedimiento para su preparacion, su uso como medicamento o agente diagnostico, asi como medicamento que las contiene.
ES2038679T3 (es) Un procedimiento para preparar derivados de dihidrobenzofurano- y cromano-carboxamidas.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
MX9205577A (es) Derivados de carbamato de 4-amino-3-isoxazolidinonas, 3-amino-1-hidroxipirrolidin-2-onas y analogos del acido 1-amino-1-ciclopropanocarboxilico, un procedimiento para su preparacion y su uso como medicamentos.
ES8507529A1 (es) Una piperazinilalcanoilanilida
ES2038176T3 (es) Un procedimiento para la preparacion de derivados del naftaleno.
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
AR008244A1 (es) Compuestos heterociclicos, procedimiento para prepararlos, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
ES450799A1 (es) Un procedimiento para la preparacion de nuevas 3-fenilespino(esobenzofuran-1,4'-piperidemo) sulfenamidas y derivados.
ES2058360T3 (es) Nuevos derivados del acido alfa-aminodicarboxilico, su obtencion y empleo.
FR2449677B1 (fr) Nouveaux derives de benzoyl-2 glycylanilides substitues, leur preparation et leur application en tant que medicaments anxiolytiques
ES2038684T3 (es) Procedimiento de preparacion de derivados de octahidroindol y de compuestos intermedios de su preparacion.
ES2117070T3 (es) Derivados de acido quinolilmetoxi-fenilacetico y de quinolilmetoxi-bencilacilo sustituidos en la posicion 2, procedimientos para su preparacion y su uso como inhibidores de la sintesis de leucotrienos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 281713

Country of ref document: ES